Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome

F. Sora, A. Iurlo, S. Sica, R. Latagliata, M. Annunziata, S. Galimberti, F. Castagnetti, P. Pregno, N. Sgherza, F. Celesti, M. Bocchia, A. Gozzini, C. Fava, D. Cattaneo, M. Crugnola, E. Montefusco, E. Mauro, I. Capodanno, M. Breccia

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)267-270
Number of pages4
JournalBritish Journal of Haematology
Volume181
Issue number2
DOIs
Publication statusPublished - 2018

Keywords

  • dasatinib
  • hydroxyurea
  • imatinib
  • nilotinib, activated partial thromboplastin time
  • adult
  • aged
  • bleeding
  • cancer chemotherapy
  • cancer survival
  • chronic myeloid leukemia
  • clinical feature
  • drug effect
  • female
  • human
  • human tissue
  • iron deficiency
  • Letter
  • major clinical study
  • male
  • outcome assessment
  • overall survival
  • platelet count
  • priority journal
  • risk reduction
  • survival time
  • thrombocytopheresis
  • thrombocytosis
  • treatment planning

Cite this

Sora, F., Iurlo, A., Sica, S., Latagliata, R., Annunziata, M., Galimberti, S., Castagnetti, F., Pregno, P., Sgherza, N., Celesti, F., Bocchia, M., Gozzini, A., Fava, C., Cattaneo, D., Crugnola, M., Montefusco, E., Mauro, E., Capodanno, I., & Breccia, M. (2018). Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome. British Journal of Haematology, 181(2), 267-270. https://doi.org/10.1111/bjh.14553